Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET-adapted R-CHOP versus standard 6-cycle R-CHOP in low-risk CD20-positive diffuse large B-cell lymphoma
2009-017279-77Phase 3Completed
- Sponsor
- GELARC
- Start
- Jul 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by GELARC. Primary endpoint: Progression-free survival at 3 years. Started Jul 2010; status: completed.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2009-017279-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017279-77.